Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease

Abstract

Letters21 January 2014Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney DiseaseJames Lineen, MB BCh, MSc and David M.J. Naimark, MD, MSc, on behalf of the Sunnybrook Nephrology Journal ClubJames Lineen, MB BCh, MScFrom Sunnybrook Health Sciences Centre and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.Search for more papers by this author and David M.J. Naimark, MD, MScFrom Sunnybrook Health Sciences Centre and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.Search for more papers by this author, on behalf of the Sunnybrook Nephrology Journal ClubSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L14-5001-5 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Erickson and colleagues (1) have published an elegant Markov-based cost-effectiveness analysis that extends the results of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) trial (2) of tolvaptan for the treatment of adult autosomal dominant polycystic kidney disease (ADPKD). The authors indicate that a key input parameter was the change in estimated glomerular filtration rate (eGFR) in patients who would or would not receive chronic tolvaptan therapy. In fact, the parameter that was modeled was the change in the actual GFR. However, because the eGFR is a nonlinear ...